Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522345-21-00

Acronym

A148_01PK2408

Enrollment

213

Registered

2025-10-26

Start date

2025-11-11

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderately to severely active ulcerative colitis, Moderate-to-severe plaque psoriasis

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Countries

Poland

Outcome results